Drugs / BCMA/CD70-targetd CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07184450 | Sep 2025 → Mar 2026 overdue | Sjogren syndrome, juvenile dermatomyositis, polyarticular juvenile idiopathic arthritis, systemic sclerosis | Chongqing Precision Biotech Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCMA/CD70-targetd CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07184450 ↗ |
| Action | Deplete | “eliminate target cells expressing disease-related antigens” NCT07184450 ↗ |
| Modality | Cell therapy | “CAR-T therapy is an adoptive cell therapy” NCT07184450 ↗ |
| Route | Intravenous | “received a single intravenous cell infusion” NCT07184450 ↗ |